The estimated Net Worth of Silvia Noiman is at least $160 Mille dollars as of 6 June 2018. Silvia Noiman owns over 349,400 units of Eloxx Pharmaceuticals Inc stock worth over $294 and over the last 6 years he sold ELOX stock worth over $0. In addition, he makes $159,600 as Director at Eloxx Pharmaceuticals Inc.
Silvia has made over 1 trades of the Eloxx Pharmaceuticals Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 349,400 units of ELOX stock worth $210 on 6 June 2018.
The largest trade he's ever made was exercising 349,400 units of Eloxx Pharmaceuticals Inc stock on 6 June 2018 worth over $210. On average, Silvia trades about 69,880 units every 0 days since 2018. As of 6 June 2018 he still owns at least 490,789 units of Eloxx Pharmaceuticals Inc stock.
You can see the complete history of Silvia Noiman stock trades at the bottom of the page.
Dr. Silvia Noiman Ph.D. serves as Director of the Company. Dr. Noiman has over 25 years of experience as an entrepreneur and executive in the biopharmaceuticals industry. Currently, she is serving as a consultant to Pontifax Venture Capital. Dr. Noiman founded Eloxx Limited in 2013 and held multiple executive roles from October 2013 to December 2017, including as Chief Executive Officer. She has served as venture partner of Pontifax IV since November 2015 and Pontifax II since 2010. Dr. Noiman founded and served as Executive Chairwoman of many of the Pontifax VC portfolio companies, including cCAM Biotherapeutics Ltd., acquired by Merck in 2015. She was also founder and Senior Vice President of Predix Pharmaceuticals Ltd., bringing a small early-stage drug discovery company from inception to a $500 million publicly traded multi-product company. Under Dr. Noiman’s leadership, Predix progressed four discovery programs to late stage clinical trials and formed significant big pharma partnerships. Prior to founding Predix, Dr. Noiman was engaged in large-scale entrepreneurial activities in the biotech industry in Israel. Dr. Noiman received a M.Sc. in population genetics and a B.Sc. in Biology from the Faculty of Life Sciences at Tel-Aviv University, an M.B.A. from Recanati School of Management at Tel-Aviv University, a Ph.D. in Molecular Biology from Tel-Aviv University and did post-doctoral work at the Weizmann Institute of Science. Dr. Noiman has published numerous papers and holds several patents. Our Board believes Dr. Noiman’s in-depth knowledge of the Company and her experience in executive roles in the biotechnology industry qualifies her to serve on our Board.
As the Director of Eloxx Pharmaceuticals Inc, the total compensation of Silvia Noiman at Eloxx Pharmaceuticals Inc is $159,600. There are 8 executives at Eloxx Pharmaceuticals Inc getting paid more, with Gregory Williams having the highest compensation of $2,690,850.
Silvia's mailing address filed with the SEC is C/O ELOXX PHARMACEUTICALS, INC., 950 WINTER STREET, WALTHAM, MA, 02451.
Over the last 7 years, insiders at Eloxx Pharmaceuticals Inc have traded over $0 worth of Eloxx Pharmaceuticals Inc stock and bought 22,391,804 units worth $47,296,070 . The most active insiders traders include Ran Nussbaum, Tomer Kariv e Steven D Rubin. On average, Eloxx Pharmaceuticals Inc executives and independent directors trade stock every 26 days with the average trade being worth of $275. The most recent stock trade was executed by Alan Edmund Walts on 1 December 2021, trading 37,695 units of ELOX stock currently worth $23.
eloxx pharmaceuticals, inc. is a clinical-stage biopharmaceutical company developing novel rna-modulating drug candidates that are designed to treat rare and ultra-rare premature stop codon diseases. premature stop codons are point mutations that disrupt protein synthesis from messenger rna. as a consequence, patients with premature stop codon diseases have reduced or eliminated protein production from the mutation bearing allele accounting for some of the most severe phenotypes in these genetic diseases. these premature stop codons have been identified in over 1,800 rare and ultra-rare diseases. read-through therapeutic development is focused on extending mrna half-life and increasing protein synthesis by enabling the cytoplasmic ribosome to read through premature stop codons to produce full-length proteins. eloxx’s lead product candidate, elx-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. elx-02 is in the early stages of clin
Eloxx Pharmaceuticals Inc executives and other stock owners filed with the SEC include: